Joanne Wuu
Overview
Explore the profile of Joanne Wuu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
6904
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koch J, Leha A, Bidner H, Cordts I, Dorst J, GuNTHER R, et al.
Lancet Neurol
. 2024 Oct;
23(11):1133-1146.
PMID: 39424560
Background: Fasudil is a small molecule inhibitor of Rho-associated kinase (ROCK) and is approved for the treatment of subarachnoid haemorrhage. In preclinical studies, fasudil has been shown to attenuate neurodegeneration,...
2.
Benatar M, Macklin E, Malaspina A, Rogers M, Hornstein E, Lombardi V, et al.
EBioMedicine
. 2024 Sep;
108:105323.
PMID: 39270623
Background: With increasing recognition of the value of incorporating prognostic markers into amyotrophic lateral sclerosis (ALS) trial design and analysis plans, there is a pressing need to understand which among...
3.
Lee I, Garret M, Wuu J, Harrington E, Berry J, Miller T, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2024 Aug;
25(7-8):672-679.
PMID: 39192497
: To examine the relationship between body mass index (BMI) and genotype among pre-symptomatic carriers of different pathogenic variants associated with amyotrophic lateral sclerosis. : carriers, carriers, and pathogenic variant...
4.
Benatar M, Macklin E, Malaspina A, Rogers M, Hornstein E, Lombardi V, et al.
medRxiv
. 2024 Aug;
PMID: 39185513
Background: With increasing recognition of the value of incorporating prognostic markers into amyotrophic lateral sclerosis (ALS) trial design and analysis plans, there is a pressing need to understand among the...
5.
Crayle J, Rampersaud E, Myers J, Wuu J, Taylor J, Wu G, et al.
Neurology
. 2024 Jul;
103(4):e209696.
PMID: 39079071
Background And Objectives: The term "ALS Reversal" describes patients who initially meet diagnostic criteria for amyotrophic lateral sclerosis (ALS) or had clinical features most consistent with progressive muscular atrophy (PMA)...
6.
Benatar M, Wuu J, Huey E, McMillan C, Petersen R, Postuma R, et al.
Nat Rev Neurol
. 2024 May;
20(6):377.
PMID: 38811858
No abstract available.
7.
Benatar M, Hansen T, Rom D, Geist M, Blaettler T, Camu W, et al.
Lancet Neurol
. 2024 May;
23(7):687-699.
PMID: 38782015
Background: Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder leading to muscle weakness and respiratory failure. Arimoclomol, a heat-shock protein-70 (HSP70) co-inducer, is neuroprotective in animal models of amyotrophic lateral...
8.
Benatar M, Wuu J, Huey E, McMillan C, Petersen R, Postuma R, et al.
Nat Rev Neurol
. 2024 May;
20(6):364-376.
PMID: 38769202
Increasing appreciation of the phenotypic and biological overlap between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, alongside evolving biomarker evidence for a pre-symptomatic stage of disease and observations that this...
9.
Margolesky J, Feldman M, Marmol S, Shpiner D, Luca C, Moore H, et al.
Neurol Clin Pract
. 2023 Dec;
14(1):e200240.
PMID: 38156119
Background And Objectives: In clinical practice, we have observed that patients with Parkinson disease (PD) often have blepharoclonus, but its prevalence is not well described in the literature. Understanding the...
10.
Benatar M, Ostrow L, Lewcock J, Bennett F, Shefner J, Bowser R, et al.
Ann Neurol
. 2023 Dec;
95(2):211-216.
PMID: 38110839
Objective: To explore whether the utility of neurofilament light chain (NfL), as a biomarker to aid amyotrophic lateral sclerosis (ALS) therapy development, would be enhanced by obtaining formal qualification from...